BioCentury
ARTICLE | Clinical News

Anthrax immune globulin IV regulatory update

August 11, 2014 7:00 AM UTC

Emergent submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product - a solution of human polyclonal antibodies that target anthrax t...